Program
lenacapavir
Also written as “Lenacapavir Tablet”, “Lenacapavir Injection” and “Lenacapavir”.
Its studies are mostly in HIV Infections, led by Gilead Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 1916 open or running | phase 4since Oct 26, 2026 | Nov 2, 2018 | Mar 2027phase 2 · NCT06749054 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Nov 2, 2018.
- Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionNCT04994509 · 5,368 enrolled · South Africa, Uganda
- Sep 13, 2021Phase 2 study in HIV-1 InfectionNCT05052996 · 142 enrolled · United States
- Aug 5, 2022Phase 3 study in HIV-1-infectionNCT05502341 · 689 enrolled · United States, Argentina, Australia and more
- Oct 20, 20232 phase 2 studies in Pre-Exposure Prophylaxis of HIV InfectionNCT06101342, NCT06101329
- Mar 20, 2024Phase 3 study in HIV-1-infectionNCT06333808 · 577 enrolled · United States, Argentina, Australia and more
- Jul 16, 2024Phase 2 study in Pre-Exposure Prophylaxis of HIV InfectionNCT06513312 · 268 enrolled · France, United Kingdom
- Jul 29, 2024Phase 3 study in HIV-1-infectionNCT06532656 · 75 enrolled · United States, Argentina, Italy and more
- Dec 19, 2024Phase 2 study in HIV-1-infectionNCT06749054 · 12 planned · United States, South Africa
- Jun 24, 2025Phase 3 study in HIV Pre-exposure ProphylaxisNCT07047716 · 339 enrolled · United States
- Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
- Jun 26, 2026Phase 3 study in HIV InfectionsNCT07682961 · 590 planned · United States, Australia, Japan
- Jul 13, 2026Phase 3 study in HIV-1-infectionNCT07708727 · 700 planned · United States, Canada, Germany and more
- Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
- Oct 26, 2026Phase 4 study in HIV-1 InfectionNCT07908446 · 400 planned
Ahead
- Mar 2027Primary completion: phase 2 study in HIV-1-infectionNCT06749054
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
- Jul 2028Primary completion: phase 4 study in HIV-1 InfectionNCT07908446
- Sep 2028Primary completion: phase 3 study in HIV Pre-exposure ProphylaxisNCT07047716
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Structural capsid protein inhibitor; Structural capsid protein inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908446HIV-1 Infection | 4 | Not yet recruiting | Jul 2028 | 400 |
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Oct 2030 | 700 |
| NCT07682961HIV Infections · United States, Australia, Japan | 3 | Recruiting | Mar 2029 | 590 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Aug 2027 | 175 |
| NCT07047716HIV Pre-exposure Prophylaxis · United States | 3 | Active, not recruiting | Sep 2028 | 339 |
| NCT06749054HIV-1-infection · United States, South Africa | 2 | Recruiting | Mar 2027 | 12 |
| NCT06532656HIV-1-infection · United States, Argentina, Italy and more | 3 | Active, not recruiting | Jul 2030 | 75 |
| NCT06513312Pre-Exposure Prophylaxis of HIV Infection · France, United Kingdom | 2 | Active, not recruiting | May 28, 2026 | 268 |
| NCT06333808HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 27, 2025 | 577 |
| NCT06101342Pre-Exposure Prophylaxis of HIV Infection · United States | 2 | Active, not recruiting | Jul 27, 2026 | 181 |
| NCT06101329Pre-Exposure Prophylaxis of HIV Infection · United States | 2 | Active, not recruiting | Jul 22, 2026 | 253 |
| NCT05502341HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 29, 2025 | 689 |
| NCT05052996HIV-1 Infection · United States | 2 | Active, not recruiting | Dec 19, 2023 | 142 |
| NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda | 3 | Active, not recruiting | May 27, 2024 | 5,368 |
| NCT04925752Pre-Exposure Prophylaxis of HIV Infection · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Aug 21, 2024 | 3,292 |
| NCT04811040HIV-1 Infection · United States | 1 | Completed | Jun 9, 2022 | 32 |
| NCT04150068HIV-1-infection · United States, Canada, Dominican Republic and more | 3 | Active, not recruiting | Oct 5, 2020 | 72 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Oct 5, 2021 | 183 |
| NCT03739866HIV-1 Infection · United States | 1 | Completed | Nov 14, 2019 | 53 |
How it is read
Names in the registry
- “Lenacapavir Tablet”, 7 entries
- “Lenacapavir Injection”, 6 entries
- “Lenacapavir”, 5 entries
- “Oral Lenacapavir”, 4 entries
- “Subcutaneous Lenacapavir”, 4 entries
Conditions, from the studies’ own filings
- HIV Infections, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.